Moderna takes millions in DARPA money, yet fails to mention taxpayer funding in its vaccine patent applications

Moderna takes millions in DARPA money, yet fails to mention taxpayer funding in its vaccine patent applications
Image: Moderna takes millions in DARPA money, yet fails to mention taxpayer funding in its vaccine patent applications

(Natural News) A new biotechnology company named Moderna is at the forefront of the covid-19 vaccination push, preparing to unleash new mRNA technology into human beings as soon as the Food and Drug Administration (FDA) grants the company emergency authorization. The new mRNA vaccine technology has been covertly funded by the “Defense Advanced Research Projects Agency” or DARPA, which is a military research branch from the Department of Defense. DARPA has already awarded $25 million to Moderna, yet this has yet to be disclosed in the 126 patents and 154 patent applications put out by Moderna.

Because of this, taxpayers are involuntarily helping to foot the bill for the new cell modification technology that inserts genetic instructions into humans so their cells will begin producing properties of the coronavirus for auto-immune experimentation. These undisclosed funds are in addition to the approximately $1 billion in taxpayer funds that were taken from the public via “Operation Warp Speed” to invest in the controversial vaccine science.

Moderna’s experimental vaccine got secretive DARPA funding, revealing dishonest motivations

Patent advocacy group KEI claims that Moderna has failed to disclose the DARPA funding, which shows Moderna’s dishonest motives from the start. These dishonest motives are even more prevalent in how the company is using their press releases to embellish the clinical studies on their experimental vaccine project, to enrich their investors and keep funds rolling in.

KEI is calling on DARPA and the Department of Defense to fix their patent applications. US federal law requires that government funding be disclosed in these circumstances. DARPA spokesman Jared Adams responded: “It appears that all past and present DARPA awards to Moderna include the requirement to report the role of government-funding for related inventions. Further, DARPA is actively researching agency awards to Moderna to identify which patents and pending patents, if any at all, may be associated with DARPA support.”

The Public Readiness and Emergency Preparedness Act, signed into law by President of the United States George W. Bush in December 2005, indemnifies vaccine manufactures from liability, as long as a public health emergency is sustained by government officials. With the Department of Defense involved in the project, it’s important to note that the DoD has the power to establish policy, assign responsibilities, and provide procedures to establish a uniform DoD immunization program.

Moderna’s experimental vaccine is now too big to fail, as investors must cash in

Because of the astronomical amount of taxpayer funds invested into Moderna, this vaccine project is too big to fail. Investors must get a return on their investment, no matter what kind of rushed clinical results are pushed through in 2020. The stock market will dictate whether this vaccine is safe and effective, and with exemptions from liability, Moderna is protected from all damages they cause to human life, even when their experimental technology harms people in the short and long term (which includes trans-generational effects). For example, the inclusion criteria for the latest Moderna vaccine clinical study mandates that “male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the time of the first dose and through 3 months after the second dose.”

Moderna’s experimental cell-modifying, gene therapy vaccine is slated to cost $37 per dose. In comparison, traditional vaccine development from AstraZeneca and the University of Oxford, is projected to cost approximately $3 per dose. These experimental jabs use lab grown, antigen-specific, chemical and biological formulations that depend on adjuvant augmentation of the individual’s immune cells.

It is neither fair nor just that taxpayers are forced to fund this project while being told they must take the vaccine and they cannot be compensated if and when the vaccine causes injury. Due to the shoddy results from the first clinical trials, (which show 100 percent of recipients showing symptoms after two injections) the American taxpayers deserve a full refund right now, and deserve an honest press release from Moderna stating the risks associated with this rushed project, no matter how the truth affects the stock market.

Sources include: